Patents matching “AXIS”

US 9005599

Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of biological or chemical agents

Tissue Regeneration Therapeutics Inc. · Granted Apr 14, 2015 · Expires Apr 9, 2035

US 8901309

Fused triazoles for the treatment or prophylaxis of mild cognitive impairment

Takeda Pharmaceutical Company Limited · Granted Dec 2, 2014 · Expires Nov 27, 2034

US 8853215

Derivatives of N-acyl-N′-phenylpiperazine useful (inter alia) for the prophylaxis or treatment of diabetes

Takeda Pharmaceutical Company Limited · Granted Oct 7, 2014 · Expires Oct 2, 2034

US 8784802

Ischemic tissue cell therapy

Cryopraxis Criobiologia Ltda. · Granted Jul 22, 2014 · Expires Jul 17, 2034

US 8729027

Therapeutic agent for fibromyalgia containing etanercept

AXIS · Granted May 20, 2014 · Expires May 15, 2034

US 8637013

Treatment of drug-related side effect and tissue damage by targeting the CD24-HMGB1-Siglec10 axis

THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Jan 28, 2014 · Expires Jan 23, 2034

US 8460643

Formulation for prophylaxis of oral cavity diseases

OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTYU “WELDUP” · Granted Jun 11, 2013 · Expires Jun 6, 2033

US 8377444

Therapeutic agent or preventive agent for osteoarthritis

AXIS · Granted Feb 19, 2013 · Expires Feb 14, 2033

US 8163281

Treatment of drug-related side effect and tissue damage by targeting the CD24-HMGB1-Siglec10 axis

THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Apr 24, 2012 · Expires Apr 19, 2032

US 7998968

Substituted pyrimidines and [1,2, 4] triazoles and the use thereof for treating prophylaxis, cardiovascular diseases, metabolic diseases and/or central nervous system diseases

Takeda Pharmaceutical Company Limited · Granted Aug 16, 2011 · Expires Aug 11, 2031

US 7803940

Heteromonocyclic compound or a salt thereof having strong antihypertensive action, insulin sensitizing activity and the like production thereof and use thereof for prophylaxis or treatment of cardiovascular diseases, metabolic diseases and/or central nervous system diseases

Takeda Pharmaceutical Company Limited · Granted Sep 28, 2010 · Expires Sep 23, 2030

US 7115577

Colorectal neoplasia prophylaxis

The Board of Regents of the University of Texas System · Granted Oct 3, 2006 · Expires Sep 28, 2026

US 6846807

Colorectal neoplasia prophylaxis

The Board of Regents of the University of Texas System · Granted Jan 25, 2005 · Expires Jan 20, 2025

US 6764681

Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction

THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Jul 20, 2004 · Expires Jul 15, 2024

US 6759044

Cryptopain antibodies for prophylaxis, treatment, diagnosis and detection of Cryptosporidium species

The Regents of the University of California · Granted Jul 6, 2004 · Expires Jul 1, 2024

US 6432434

Treatment of and/or prophylaxis against brain and spinal cord injury

The United States of America as represented by the Secretary of the Army · Granted Aug 13, 2002 · Expires Aug 8, 2022

US 6420134

Vaccines for nontypable haemophilus influenzae

Praxis Biologics, Inc. · Granted Jul 16, 2002 · Expires Jul 11, 2022

US 6296607

In situ bulking device

Praxis Holding LLC · Granted Oct 2, 2001 · Expires Sep 27, 2021

US 6265539

Prophylaxis and therapy of acquired immunodeficiency syndrome

THE UNIVERSTY OF TEXAS SYSTEM,BOARD OF REGENTS · Granted Jul 24, 2001 · Expires Jul 19, 2021

US 6254869

Cryptopain vaccines, antibodies, proteins, peptides, DNA and RNA for prophylaxis, treatment and diagnosis and for detection of cryptosporidium species

The Regents of the University of California · Granted Jul 3, 2001 · Expires Jun 28, 2021

US 6183752

Restenosis/atherosclerosis diagnosis, prophylaxis and therapy

The United States of America, as represented by the Department of Health and Human Services · Granted Feb 6, 2001 · Expires Feb 1, 2021

US 6162432

Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction

THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Dec 19, 2000 · Expires Dec 14, 2020

US 6159958

Treatment or prophylaxis of retinal pathology and spinal cord injury

The United States of America as represented by the Secretary of the Army · Granted Dec 12, 2000 · Expires Dec 7, 2020

US 6015882

Vaccines, antibodies, proteins, glycoproteins, DNAs and RNAs for prophylaxis and treatment of Cryptosporidium parvum infections

The Regents of the University of California · Granted Jan 18, 2000 · Expires Jan 13, 2020